<DOC>
	<DOCNO>NCT02602444</DOCNO>
	<brief_summary>The purpose PINPOINT study compare pharmacokinetics ( PK ) pharmacodynamics ( PD ) ticagrelor ST-elevation myocardial infarction ( STEMI ) non-ST-elevation myocardial infarction ( NSTEMI ) patient designate invasive strategy . Data regard comparison PK antiplatelet action ticagrelor STEMI NSTEMI sparse . Recommended dose regimen ticagrelor identical STEMI NSTEMI , although know whether PK PD feature ticagrelor uniform patient .</brief_summary>
	<brief_title>Comparison Ticagrelor Pharmacokinetics Pharmacodynamics STEMI NSTEMI Patients</brief_title>
	<detailed_description>The European Society Cardiology American Heart Association guideline recommend use ticagrelor prasugrel treatment choice patient STEMI NSTEMI ( class recommendation I , level evidence B ) . Recommended dose regimen ticagrelor identical STEMI NSTEMI patient , although epidemiology , clinical approach early outcome differ two type myocardial infarction . It know whether PK PD feature ticagrelor uniform STEMI NSTEMI patient . However , exist body evidence suggest PK PD ticagrelor may attenuate STEMI patient compare healthy subject patient stable coronary artery disease , may expose STEMI patient increase risk develop thrombotic complication secondary insufficient platelet inhibition . The PINPOINT study could provide valuable insight knowledge regard ticagrelor action STEMI vs. NSTEMI patient . Since reference study compare pharmacokinetics ticagrelor STEMI NSTEMI patient , decide perform internal pilot study approximately 30 patient ( 15 patient type myocardial infarction ) estimate final sample size .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>provision inform consent prior study specific procedure diagnosis acute STsegment elevation myocardial infarction acute nonSTsegment elevation myocardial infarction male nonpregnant female , 18 year old old provision inform consent angiography PCI treatment ticlopidine , clopidogrel , prasugrel ticagrelor within 14 day study enrollment hypersensitivity ticagrelor current treatment oral anticoagulant chronic therapy lowmolecularweight heparin active bleed history intracranial hemorrhage recent gastrointestinal bleeding ( within 30 day ) history coagulation disorder history moderate severe hepatic impairment history major surgery severe trauma ( within 3 month ) second third degree atrioventricular block screen eligibility patient require dialysis manifest infection inflammatory state Killip class III IV screen eligibility respiratory failure current therapy strong CYP3A inhibitor strong CYP3A inducer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>